



State of North Dakota
Doug Burgum, Governor

OFFICE OF THE EXECUTIVE DIRECTOR
1906 E Broadway Ave
Bismarck ND 58501-4700
Telephone (701) 328-9535
Fax (701) 328-9536
STATE BOARD OF PHARMACY

Mhardy@ndboard.pharmacy
www.nodakpharmacy.com

Mark J. Hardy, PharmD, R.Ph.
Executive Director

Senate Bill No 2212 – Prescription Drug Importation Study

House Human Services Committee – Pioneer Room
9:00 AM - Tuesday – March 9th, 2021

Chairman Weisz, members of the House Human Services Committee, for the record I am Mark J. Hardy, PharmD, Executive Director of the North Dakota State Board of Pharmacy. I appreciate the opportunity to be here to speak to you today about Senate Bill 2212 and offer our perspective on this bill.

The Board of Pharmacy stands ready and willing to act on this study to further explore policies that may be determined to be appropriate to be implemented for the State of North Dakota.

Certainly, there will be many policy solutions that could be examined by the Legislature. A couple of which you will hear in future Bill Testimonies regarding Importation and reference pricing.

Prescription Drug Pricing is a very contentious issue. Our office often hears from citizens about issues involved in drug pricing that could impede their care. We have been encouraged by some of the recent actions by the previous administration to take a hard look at prescription drug pricing from a Federal perspective. It will be interesting to see if those initiatives continue to be policy solutions moving forward.

The Board of Pharmacy supports Senate Bill 2212 and looks forward to being of assistance and providing perspective to the Study in the interim.

If you have any questions, I would be happy to answer them at this time.